Centocor Ortho Biotech Products, L.P. today announced that it received a Complete Response letter from the U.S. FDA regarding the New Drug Application (NDA) for trabectedin when administered in combination with DOXIL (doxorubicin HCI liposome injection) for the treatment of women with relapsed ovarian cancer.
The details can be read here.
No comments:
Post a Comment